% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{PtterNerger:272581,
      author       = {Pötter-Nerger, Monika and Löhle, Matthias and Höglinger,
                      Günter},
      collaboration = {Group, German Parkinson‘s Guideline},
      title        = {{A}kinetic crisis and withdrawal syndromes: guideline
                      '{P}arkinson's disease' of the {G}erman {S}ociety of
                      {N}eurology.},
      journal      = {Journal of neurology},
      volume       = {271},
      number       = {10},
      issn         = {0367-004X},
      address      = {Heidelberg},
      publisher    = {Springer},
      reportid     = {DZNE-2024-01202},
      pages        = {6485 - 6493},
      year         = {2024},
      abstract     = {The akinetic crisis is a well-known, rare, potentially
                      life-threatening condition in Parkinson's disease with
                      subacute worsening of akinesia, rigidity, fever, impaired
                      consciousness, accompanying vegetative symptoms and
                      transient dopa-resistance. The akinetic crisis was
                      historically supposed to be a 'withdrawal syndrome' in the
                      sense of discontinuation of dopaminergic medication.
                      Recently, other 'withdrawal syndromes' as the specific
                      'dopamine agonist withdrawal syndrome' or 'deep brain
                      stimulation withdrawal syndrome' have been described as
                      emergency situations with specific subacute symptom
                      constellations. All three conditions require immediate start
                      of the adequate therapy to improve the prognosis. Here, the
                      diagnostic criteria and treatment options of these three
                      acute, severely disabling syndromes will be reported along
                      the current guidelines of the German Parkinson Guideline
                      Group.},
      subtyp        = {Review Article},
      keywords     = {Humans / Parkinson Disease: drug therapy / Parkinson
                      Disease: diagnosis / Parkinson Disease: therapy / Substance
                      Withdrawal Syndrome: diagnosis / Germany / Neurology:
                      standards / Societies, Medical: standards / Antiparkinson
                      Agents: therapeutic use / Antiparkinson Agents: adverse
                      effects / Deep Brain Stimulation: standards / Practice
                      Guidelines as Topic: standards / Akinetic crisis (Other) /
                      Deep brain stimulation withdrawal syndrome (Other) /
                      Diagnostic criteria (Other) / Dopamine agonist withdrawal
                      syndrome (Other) / German Parkinson Guideline (Other) /
                      Therapy (Other) / Antiparkinson Agents (NLM Chemicals)},
      cin          = {Clinical Research (Munich) / AG Höglinger / AG Teipel},
      ddc          = {610},
      cid          = {I:(DE-2719)1111015 / I:(DE-2719)1110002 /
                      I:(DE-2719)1510100},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39192030},
      pmc          = {pmc:PMC11447035},
      doi          = {10.1007/s00415-024-12649-x},
      url          = {https://pub.dzne.de/record/272581},
}